Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics reported a narrower full-year 2025 net loss of $43.4 million, improved from $69.2 million in 2024, as it advanced its lead retinal drug candidate TH103.
Cash, cash equivalents and marketable securities rose to $118.0 million as of December 31, 2025, from $1.6 million a year earlier, driven by its March 2025 merger with AlloVir and an oversubscribed $50.0 million private placement in December. The company expects this cash to fund operations into the fourth quarter of 2027.
Research and development expenses fell to $30.8 million from $45.0 million, largely reflecting a prior-year royalty obligation, while general and administrative costs increased to $15.4 million from $6.7 million as Kalaris scaled public-company infrastructure. Shares outstanding were 22,902,418 as of December 31, 2025.
Clinically, Kalaris reported positive initial Phase 1a single ascending dose data in neovascular age-related macular degeneration, noting TH103 was generally well tolerated with no dose-limiting toxicities or treatment-related serious adverse events. An ongoing Phase 1b/2 multiple ascending dose trial began enrolling in 2025, with preliminary data expected in the first half of 2027, and the company intends to start Phase 3 trials by year-end 2027.
Kalaris Therapeutics, Inc. furnished an updated corporate presentation outlining development plans and early data for its lead retinal therapy candidate, TH103. The company highlights TH103 as an engineered anti-VEGF fusion protein designed for extended intraocular retention and enhanced VEGF inhibition in neovascular retinal diseases such as nAMD.
Initial Phase 1a single-ascending dose data showed rapid, robust improvements in visual acuity and retinal fluid measures at one month, with TH103 generally well tolerated and no dose-limiting toxicities reported. An ongoing Phase 1b/2 multi-dose trial in nAMD is underway, with preliminary data expected in the first half of 2027 and potential Phase 3 initiation planned by year-end 2027, subject to results.
The presentation also notes a $50 million oversubscribed private placement completed in December 2025 and states that the company’s cash runway is expected to fund operations into the fourth quarter of 2027. Kalaris emphasizes continued manufacturing process refinements aimed at reducing host cell protein levels and outlines intellectual property protection for TH103 compositions and methods of use, with U.S. exclusivity expected into the early 2040s.
Kalaris Therapeutics, Inc. reported an insider-related block trade in its common stock involving affiliated investment funds. Samsara Opportunity Fund, L.P., an entity associated with director and 10% owner Srinivas Akkaraju, made an open-market style, privately negotiated purchase of 479,847 common shares at $10.42 per share from Samsara BioCapital, L.P.
Following this transaction, Samsara Opportunity Fund held 1,979,847 Kalaris Therapeutics shares, while Samsara BioCapital, L.P. held 10,968,234 shares. The filing notes that Akkaraju and related general partner entities may be deemed beneficial owners but disclaim beneficial ownership beyond their pecuniary interests, and one footnote states the transfer from Samsara BioCapital, L.P. did not change Akkaraju’s overall beneficial ownership.
Samsara BioCapital–affiliated funds and Srinivas Akkaraju updated their ownership disclosure in Kalaris Therapeutics through an amendment to their Schedule 13D. Dr. Akkaraju is reported to beneficially own 12,954,081 shares of common stock, or 56.5% of the company, including 6,000 stock options exercisable within 60 days.
The filing shows 10,968,234 shares (47.9%) held by Samsara BioCapital, L.P. and 1,979,847 shares (8.6%) held by Samsara Opportunity Fund, L.P. On December 18, 2025, Samsara Opportunity Fund bought 479,847 shares from Samsara LP in a private sale at $10.42 per share, for a total of $5,000,005.74, funded by its partners’ capital contributions.
RTW Investments, LP and Roderick Wong reported beneficial ownership of 1,300,000 shares of Kalaris Therapeutics common stock, representing 5.7% of the class. The shares are held by RTW-managed funds, with RTW Investments as investment adviser and Dr. Wong as managing partner and CIO.
Both reporting persons have shared voting and dispositive power over the 1,300,000 shares and no sole voting or dispositive power. The 5.7% figure is based on 18,702,418 shares outstanding as of November 5, 2025 plus 4,200,000 shares issued in a December 2025 private placement. The holders certify the stake is held in the ordinary course and not for influencing control.
Kalaris Therapeutics, Inc. entered into a private placement with institutional accredited investors to raise approximately $50.0 million in gross proceeds. The company agreed to sell 4,200,000 shares of common stock at $10.00 per share and issue pre-funded warrants to purchase 800,000 shares of common stock at $9.9999 per warrant, each warrant carrying an exercise price of $0.0001 per share and being exercisable immediately until fully exercised.
The private placement is expected to close on or about December 19, 2025, subject to customary conditions, with Morgan Stanley & Co. LLC and Leerink Partners LLC as lead placement agents. Kalaris expects that its cash, cash equivalents and short-term investments, together with anticipated net proceeds from this financing, will be sufficient to fund operating expenses and capital expenditures into the third quarter of 2027. The company also agreed to register the resale of the new shares and warrant shares under a future registration rights agreement.
Kalaris Therapeutics reported initial data from its Phase 1a single ascending dose trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration. The study used a single intravitreal injection at three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in 13 patients who completed six months of follow-up and showed robust improvements in vision and retinal anatomy that are consistent with TH103’s molecular design and preclinical profile.
TH103 was generally well tolerated. Two cases of transient, mild to moderate intraocular inflammation occurred at the 2.5 mg dose and were linked to host cell protein levels in the drug product; after adding extra purification steps, six more patients received the 2.5 mg dose with the new material and no additional inflammation events were seen at one week or more of follow-up. The company is using this updated drug product in ongoing and planned studies and is enrolling a Phase 1b/2 multi-ascending dose, dose-finding trial of four monthly injections, with preliminary data expected in the second half of 2026.
Kalaris Therapeutics (KLRS) filed its Q3 2025 10‑Q, reporting a net loss of $11.9 million for the quarter on total operating expenses of $12.7 million (research and development $9.1 million; general and administrative $3.6 million). Year to date, the net loss was $33.4 million.
As of September 30, 2025, cash, cash equivalents and short‑term investments were $77.0 million, and management states these resources are expected to fund operations for at least twelve months. The balance sheet showed total assets of $81.2 million and stockholders’ equity of $41.9 million. A royalty obligation to a related party of $32.1 million remains on the balance sheet.
Kalaris completed a reverse recapitalization with AlloVir on March 18, 2025, bringing $102.1 million of cash and resulting in 18,702,418 shares outstanding post‑merger. The company focuses on TH103, a clinical‑stage anti‑VEGF candidate for retinal diseases. Quarterly loss per share was $0.64.
Kalaris Therapeutics (KLRS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference as stated.
The company notes the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act. Kalaris Therapeutics’ common stock trades on The Nasdaq Global Market under the symbol KLRS.
Kalaris Therapeutics (KLRS) reported a Form 4 for CFO Matthew Gall, showing a grant of stock options for 235,000 shares at an exercise price of $4.99 on November 3, 2025.
The options expire on November 2, 2035 and vest over four years: 25% on November 3, 2026, then the remainder in equal monthly installments, subject to continuous service. Following the grant, 235,000 derivative securities were beneficially owned directly.